Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year
BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphoma
Application supported by Phase 3
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer
Brain-penetrant PRMT5 inhibitor shows promising
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months
TEVIMBRA-containing arm was associated with a
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline
Multiple
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing
BeOne Medicines, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA
ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status
Regimen poised to become
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028
BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX:
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers
Regional rights agreement provides BeOne
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year
BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the
$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities
Creates 120 new full-time jobs to support
